Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,257 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study.
Khutsoane D, Sharma SK, Almustafa M, Jang HC, Azar ST, Danciulescu R, Shestakova M, Ayad NM, Guler S, Bech OM; PRESENT Study Group. Khutsoane D, et al. Among authors: sharma sk. Diabetes Obes Metab. 2008 Mar;10(3):212-22. doi: 10.1111/j.1463-1326.2007.00826.x. Diabetes Obes Metab. 2008. PMID: 18269636 Clinical Trial.
Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes.
Bode BW, Testa MA, Magwire M, Hale PM, Hammer M, Blonde L, Garber A; LEAD-3 Study Group. Bode BW, et al. Diabetes Obes Metab. 2010 Jul;12(7):604-12. doi: 10.1111/j.1463-1326.2010.01196.x. Diabetes Obes Metab. 2010. PMID: 20590735 Free PMC article. Clinical Trial.
Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes.
Garber A, Henry RR, Ratner R, Hale P, Chang CT, Bode B; LEAD-3 (Mono) Study Group. Garber A, et al. Diabetes Obes Metab. 2011 Apr;13(4):348-56. doi: 10.1111/j.1463-1326.2010.01356.x. Diabetes Obes Metab. 2011. PMID: 21205128 Free PMC article. Clinical Trial.
Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes.
Gough SC, Bode B, Woo V, Rodbard HW, Linjawi S, Poulsen P, Damgaard LH, Buse JB; NN9068-3697 (DUAL-I) trial investigators. Gough SC, et al. Lancet Diabetes Endocrinol. 2014 Nov;2(11):885-93. doi: 10.1016/S2213-8587(14)70174-3. Epub 2014 Sep 1. Lancet Diabetes Endocrinol. 2014. PMID: 25190523 Clinical Trial.
Lessons in initiating insulin in clinical practice.
Sharma SK, Yeo JP, Garber A. Sharma SK, et al. Diabetes Res Clin Pract. 2008 Sep;81 Suppl 1:S16-22. doi: 10.1016/j.diabres.2008.06.009. Epub 2008 Jul 30. Diabetes Res Clin Pract. 2008. PMID: 18672308 Review.
Rising cost of insulin: A deterrent to compliance in patients with diabetes mellitus.
Zargar AH, Kalra S, K M PK, Murthy S, Negalur V, Rajput R, Rastogi A, Saboo B, Sharma SK, Sahay R, Aravind SR, Shaikh S, Tiwaskar M, Ingole S, Kamble S. Zargar AH, et al. Among authors: sharma sk. Diabetes Metab Syndr. 2022 Aug;16(8):102528. doi: 10.1016/j.dsx.2022.102528. Epub 2022 Jun 2. Diabetes Metab Syndr. 2022. PMID: 35863268 Review.
3,257 results